Literature DB >> 34045102

Feasibility assessment of measles and rubella eradication.

William J Moss1, Stephanie Shendale2, Ann Lindstrand2, Katherine L O'Brien2, Nikki Turner3, Tracey Goodman2, Katrina Kretsinger2.   

Abstract

This report addresses the epidemiological aspects and feasibility of measles and rubella eradication and the potential resource requirements in response to the request of the Director-General at the Seventieth World Health Assembly held on May 31, 2017. A guiding principle is that the path toward measles and rubella eradication should serve to strengthen primary health care, promote universal health coverage, and be a pathfinder for new vision and strategy for immunization over the next decade as laid out in the Immunization Agenda 2030. Specifically, this report: 1) highlights the importance of measles and rubella as global health priorities; 2) reviews the current global measles and rubella situation; 3) summarizes prior assessments of the feasibility of measles and rubella eradication; 4) assesses the progress and challenges in achieving regional measles and rubella elimination; 5) assesses additional considerations for measles and rubella eradication, including the results of modelling and economic analyses; 6) assesses the implications of establishing a measles and rubella eradication goal and the process for setting an eradication target date; 7) proposes a framework for determining preconditions for setting a target date for measles and rubella eradication and how these preconditions should be understood and used; and 8) concludes with recommendations endorsed by SAGE.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Elimination; Eradication; Measles; Rubella; World Health Organization

Year:  2021        PMID: 34045102     DOI: 10.1016/j.vaccine.2021.04.027

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Evaluation of Diagnostic Accuracy of Eight Commercial Assays for the Detection of Rubella Virus-Specific IgM Antibodies.

Authors:  Joanne Hiebert; Vanessa Zubach; Carmen L Charlton; Jayne Fenton; Graham A Tipples; Kevin Fonseca; Alberto Severini
Journal:  J Clin Microbiol       Date:  2021-10-27       Impact factor: 5.948

2.  Feasibility of measles and rubella vaccination programmes for disease elimination: a modelling study.

Authors:  Amy K Winter; Brian Lambert; Daniel Klein; Petra Klepac; Timos Papadopoulos; Shaun Truelove; Colleen Burgess; Heather Santos; Jennifer K Knapp; Susan E Reef; Lidia K Kayembe; Stephanie Shendale; Katrina Kretsinger; Justin Lessler; Emilia Vynnycky; Kevin McCarthy; Matthew Ferrari; Mark Jit
Journal:  Lancet Glob Health       Date:  2022-10       Impact factor: 38.927

Review 3.  Accelerating the Development of Measles and Rubella Microarray Patches to Eliminate Measles and Rubella: Recent Progress, Remaining Challenges.

Authors:  Mateusz Hasso-Agopsowicz; Natasha Crowcroft; Robin Biellik; Christopher J Gregory; Marion Menozzi-Arnaud; Jean-Pierre Amorij; Philippe-Alexandre Gilbert; Kristen Earle; Collrane Frivold; Courtney Jarrahian; Mercy Mvundura; Jessica J Mistilis; David N Durrheim; Birgitte Giersing
Journal:  Front Public Health       Date:  2022-03-02

4.  Performance of SARS-CoV-2 Antigens in a Multiplex Bead Assay for Integrated Serological Surveillance of Neglected Tropical and Other Diseases.

Authors:  Sarah Gwyn; Ado Abubakar; Oluwaseun Akinmulero; Eric Bergeron; Ugboaja Nkechi Blessing; Jasmine Chaitram; Melissa M Coughlin; Ayuba B Dawurung; Felicia Nwatu Dickson; Mudiaga Esiekpe; Erasogie Evbuomwan; Stacie M Greby; Nnaemeka C Iriemenam; Markus H Kainulainen; Thomas Andrew Naanpoen; Loveth Napoloen; Ifeanyichukwu Odoh; McPaul Okoye; Temitope Olaleye; Amy J Schuh; S Michele Owen; Awala Samuel; Diana L Martin
Journal:  Am J Trop Med Hyg       Date:  2022-06-27       Impact factor: 3.707

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.